As many as 15 employees are expected to be hired at a new Greenwood drug-making company this year.
Elona Biotechnologies expects that it will finish construction on its 50,000-square-foot manufacturing facility this year. The company will need to start adding employees to create batches of the generic insulin it hopes to sell worldwide, chief operating officer Ron Zimmerman Jr. said.
The company will have to make a batch of the drug to get U.S. Food and Drug Administration approval to sell it in the United States.
But until then, Elona plans to sell pharmaceuticals in countries with less strict regulations, Zimmerman said.
Greenwood is giving the company $8.5 million in incentives, including a construction loan to build the plant in an eastside business park. The company plans to create 70 high-paying jobs.